Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial (Q34655680)

3 August 2017

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial (English)

1 reference

randomized controlled trial

3 August 2017

1 reference

James W Murrough

1

1 reference

3 August 2017

Dan V Iosifescu

2

1 reference

3 August 2017

Lee C Chang

3

1 reference

3 August 2017

Rayan K Al Jurdi

4

1 reference

3 August 2017

Charles E Green

5

1 reference

3 August 2017

Andrew M Perez

6

1 reference

3 August 2017

Syed Iqbal

7

1 reference

3 August 2017

Sarah Pillemer

8

1 reference

3 August 2017

Alexandra Foulkes

9

1 reference

3 August 2017

Asim Shah

10

1 reference

3 August 2017

Dennis S Charney

11

1 reference

3 August 2017

Sanjay J Mathew

12

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 October 2013

1 reference

American Journal of Psychiatry

3 August 2017

1 reference

3 August 2017

170

1 reference

3 August 2017

10

1 reference

3 August 2017

1134-1142

1 reference

Synaptic mechanisms underlying rapid antidepressant action of ketamine

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Synaptic dysfunction in depression: potential therapeutic targets

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Is there anything really novel on the antidepressant horizon?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Ketamine for depression: where do we go from here?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Ketamine for treatment-resistant unipolar depression: current evidence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Review of pharmacological treatment in mood disorders and future directions for drug development.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Grand challenges in global mental health

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Therapeutic options for treatment-resistant depression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Glutamate-based antidepressants: 20 years on.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

The molecular neurobiology of depression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Medication augmentation after the failure of SSRIs for depression.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

The definition and meaning of treatment-resistant depression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Antidepressant effects of ketamine in depressed patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

The Inventory of Depressive Symptomatology (IDS): psychometric properties.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Induction dose-response curves for midazolam and ketamine in premedicated ASA class III and IV patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

A New Depression Scale Designed to be Sensitive to Change

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Pharmacological properties of ketamine.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992936

Basic dimensions of change in the symptomatology of chronic schizophrenics

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23982301

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23982301

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23982301

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1176/APPI.AJP.2013.13030392

1 reference

3 August 2017

1 reference

3 August 2017

1 reference